SOPHiA GENETICS (NASDAQ:SOPH) CFO Sells $11,775.44 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CFO George Cardoza sold 2,413 shares of the company’s stock in a transaction that occurred on Tuesday, April 7th. The shares were sold at an average price of $4.88, for a total value of $11,775.44. Following the sale, the chief financial officer owned 292,861 shares in the company, valued at $1,429,161.68. The trade was a 0.82% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

George Cardoza also recently made the following trade(s):

• On Wednesday, April 8th, George Cardoza sold 1,403 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $6,804.55.
• On Monday, April 6th, George Cardoza sold 2,520 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.85, for a total value of $12,222.00.
• On Thursday, March 19th, George Cardoza sold 774 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $4.79, for a total value of $3,707.46.

SOPHiA GENETICS Trading Down 0.6%

Shares of NASDAQ SOPH opened at $4.70 on Friday. The stock’s 50 day moving average price is $4.75 and its two-hundred day moving average price is $4.69. SOPHiA GENETICS SA has a 52-week low of $2.58 and a 52-week high of $5.70. The stock has a market capitalization of $321.90 million, a P/E ratio of -9.22 and a beta of 1.04. The company has a quick ratio of 1.84, a current ratio of 1.96 and a debt-to-equity ratio of 1.01.

SOPHiA GENETICS (NASDAQ:SOPH) last announced its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.20) by ($0.08). SOPHiA GENETICS had a negative net margin of 44.22% and a negative return on equity of 50.60%. The firm had revenue of $21.71 million for the quarter, compared to analyst estimates of $21.20 million. On average, analysts anticipate that SOPHiA GENETICS SA will post -0.96 earnings per share for the current fiscal year.

Key Stories Impacting SOPHiA GENETICS

Here are the key news stories impacting SOPHiA GENETICS this week:

• Positive Sentiment: Large institutional accumulation — UBS, Akre and several other funds materially increased positions in recent quarters, signaling conviction from some large investors which could provide demand support for the stock.
• Positive Sentiment: Analyst upside — Guggenheim and BTIG have issued Buy ratings and target prices around $7, above the current trading level, giving the stock upside on positive research momentum.
• Neutral Sentiment: Multiple executives sold small blocks of shares under pre‑arranged Rule 10b5‑1 plans to cover tax withholding associated with vested awards; these are routine and reduce the informational signal from insider sales. Representative SEC filing for CEO sales. CEO Form 4
• Neutral Sentiment: Additional planned sales by other insiders (CFO, President, CTO and others) were disclosed; most trades are modest relative to executive holdings and were executed under 10b5‑1 plans — still worth monitoring for short‑term supply impact. Example coverage of a recent insider sale. InsiderTrades article
• Negative Sentiment: Short interest increased ~20% in late March to ~255k shares (≈0.4% of float), raising potential downward pressure and the possibility of elevated volatility if shorts add to positions or cover into thin trading days.
• Negative Sentiment: Recent fundamentals remain challenged — SOPH reported an EPS miss in early March and continues to show negative margins and ROE; analysts still model negative EPS for the year, which keeps valuation sensitivity high.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on SOPH. BTIG Research restated a “buy” rating and set a $7.00 price objective on shares of SOPHiA GENETICS in a research note on Tuesday, March 3rd. Weiss Ratings restated a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Thursday, January 22nd. Finally, Guggenheim increased their price target on SOPHiA GENETICS from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Monday, January 26th. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, SOPHiA GENETICS has a consensus rating of “Hold” and a consensus target price of $7.00.

Institutional Trading of SOPHiA GENETICS

A number of institutional investors and hedge funds have recently made changes to their positions in SOPH. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its position in shares of SOPHiA GENETICS by 246.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock worth $25,341,000 after purchasing an additional 5,432,871 shares during the period. Akre Capital Management LLC raised its position in shares of SOPHiA GENETICS by 66.2% during the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares during the period. Alta Wealth Advisors LLC acquired a new stake in shares of SOPHiA GENETICS during the 3rd quarter worth approximately $6,708,000. Royce & Associates LP acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $2,009,000. Finally, 1492 Capital Management LLC acquired a new stake in shares of SOPHiA GENETICS during the 4th quarter worth approximately $973,000. 31.59% of the stock is currently owned by institutional investors and hedge funds.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.